ClinicalTrials.gg
Not yet recruitingNCT06340490Updated Apr 1, 2024

A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)

A Phase 1 interventional study of RJMty19 (CD19-CAR-DNT cells) in Systemic Lupus Erythematosus, sponsored by Guangdong Ruishun Biotech Co., Ltd. Not yet recruiting at 4 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-01.

Sponsored by Guangdong Ruishun Biotech Co., Ltd · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
145th of 245
24 · median 36
Started
2024
with 42 others
Phase 1
109 of 266
85 open now
Primary completion
2026-12
later than 72 of 190 live
Registered
114th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 145th largest by planned enrollment of the 245 interventional ones that give a count, is one of 43 that started in 2024, is one of 109 in phase 1, reaches primary completion later than 72 of the 190 other live ones, and was the 114th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, single-arm, dose escalation and dose expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic characteristics of allogeneic CD19-CAR-DNT cells (RJMty19) after infusion, and preliminary efficacy in systemic lupus erythematosus (SLE) subjects.

Read the detailed description

The dose escalation part (Part A) plans to enroll 9-18 subjects with refractory SLE receiving RJMty19 infusion to determine the maximum tolerated dose (MTD) and/or RP2D of RJMty19. The dose expansion part (Part B) plans to enroll 3-6 subjects. The Safety Review Committee (SRC) monitors the safety information of the subjects and evaluates the safety data of each dose group. To ensure the quality of the experiment, the sponsor and inverstigators will jointly discuss and formulate the clinical research plan before the formal experiment begins.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • off-the-shelf cell product
  • CAR-DNT
  • Cell Therapy
  • Autoimmune Disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign an ICF and expect to complete the subsequent follow-up.
  2. Age 18~65 years old (including cut-off value), gender is not limited.
  3. Diagnosed with SLE according to the 2019 EULAR/ACR version of the revised criteria.
  4. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥ 8 points; Anti-nuclear antibody titer ANA≥1:80, or positive anti-dsDNA and/or anti-Sm antibodies.
  5. Presence of active organ involvement.
  6. Having appropriate organ function, and the laboratory test results within 7 days before the lymphodepletion must meet the following criteria:

    1. Coagulation function:

      • Fibrinogen ≥1.0 g/L;
      • ≤ 1.5 times the (ULN);
      • Prothrombin time (PT) ≤ 1.5 times ULN.
    2. Liver function:

      • Glutathione aminotransferase () ≤ 3 times the upper limit of normal (ULN);
      • Glutamic aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN);
      • Total ≤ 1.5 times ULN, unless the subject has documented Gilbert syndrome;
      • Subjects with Gilbert-Meulengracht syndrome with total bilirubin ≤ 3.0 times ULN and direct bilirubin ≤ 1.5 times ULN may be included.
    3. Renal function:

      • Serum creatinine ≤ 1.5 times ULN or a ≥ 60 ml/min;
    4. Complete blood count:

      • ≥ 80 g/L;
      • (ANC) ≥ 1.0 x 10\^9/L;
      • count ≥ 50 x 10\^9/L;
    5. Cardiopulmonary function:

      • (LVEF) ≥ 45%;
      • Oxygen saturation ≥ 91%
  7. Female patients with of should have a negative pregnancy test during the screening period. Any male and female patients of childbearing potential must agree to use an effective method for at least six months from the time that they sign the form until the end of the cell infusion. Female subjects with non-childbearing potential (meeting at least 1 of the following criteria) is described below:

    1. Have undergone a hysterectomy or bilateral oophorectomy;
    2. Medically recognised ovarian failure;
    3. Medically recognised as (at least 12 consecutive months of menopause without pathological or physiological cause).
  8. Use of hormones and at least two standard and at least one biological agent for more than six months without meeting the LLDAS criteria; or allergy, intolerance and other drug-related side effects to the components of the biological agent make it impossible for the user to continue;
  9. greater than 6 months;
  10. Confirmed presence of CD19 positive B cells in peripheral blood by flow cytometry.

Exclusion criteria

Exclusion Criteria:

  1. Other within 5 years prior to screening, except adequately treated non-melanoma skin cancer (basal cell carcinoma or squamous cell carcinoma) or carcinoma in situ of the cervix;
  2. Major surgery requiring hospitalization within 4 weeks prior to screening or during screening;
  3. History of severe drug allergies or anaphylactic constitution;
  4. Renal disease: Diagnosed with active severe lupus nephritis within 8 weeks prior to screening, requiring treatment with drugs prohibited by the study protocol for the treatment of active nephritis, hemodialysis or prednisone dose ≥ 100 mg/d, or equivalent for ≥14 days; rate \< 60mL/min and serum creatinine > 1.5 times within 1 week before lymphodepleting chemotherapy;
  5. Central nervous system diseases: those with active central nervous system diseases caused by SLE or non-SLE (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis);
  6. Cardiovascular disease: unstable angina, myocardial infarction, class III or IV cardiac insufficiency, hypertension (The definition of refractory hypertension is: on the basis of improving lifestyle, reasonable and tolerable use of ≥3 antihypertensive drugs (including diuretics) for more than 1 month, blood pressure still not reached the target (systolic blood pressure≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg) or taking ≥4 antihypertensive drugs to effectively control blood pressure) and a history of severe arrhythmias requiring medication;
  7. Positive surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer test higher than the lower limit of the detection value, virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA positive, (HIV) antibody positive, cytomegalovirus (CMV) DNA test positive, syphilis test positive;
  8. Presence of active or uncontrollable infection requiring systemic treatment (other than simple urinary tract infection or upper respiratory tract infection) and currently receiving suppressive therapy for any chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria); untreated latent tuberculosis infection;
  9. There is clinical evidence showing the presence of important, unstable, or uncontrolled acute or chronic diseases not caused by SLE (i.e. cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignant tumors, or infectious diseases), which researchers believe may confound the study results or expose subjects to unnecessary risks;
  10. Vaccination with live or attenuated within 1 month before screening;
  11. History of/preparing to undergo organ transplantation or hematopoietic stem cell transplantation;
  12. Received CAR-T therapy or other gene-modified cell therapy prior to enrolment;
  13. Have received any of the following treatments for SLE:

    1. Use of therapeutic doses of corticosteroids (defined as prednisone or equivalent> 20 mg/d) within 72 hours prior to lymphodepleting chemotherapy or RJMty19 infusion;
    2. Treatment of SLE with any other clinical agent within 4 weeks prior to enrollment. However, enrollment is allowed if the study treatment period is ineffective or the disease has progressed, and at least 3 half-lives have elapsed prior to enrollment;
    3. Received belimumab within 8 weeks and anti-CD20 monoclonal antibody (e.g., rituximab) within 6 months prior to screening;
    4. Blood transfusion, packed red blood cells, and transfusion within 6 weeks prior to enrollment;
    5. Plasmapheresis and plasmapheresis were treated within 3 months prior to enrollment;
  14. Congenital immunoglobulin deficiency;
  15. Participated in other clinical studies within the previous 3 months, except for clinical studies that have been evaluated by the investigator as not interfering with the safety and efficacy of the study drug, such as non-intervention observational studies;
  16. In the judgment of the investigator and/or clinical criteria, there are to any of the study procedures or other medical conditions that may expose to unacceptable risks;
  17. Presence of other diseases that may interfere with the evaluation of efficacy (including but not limited to: rheumatoid arthritis, spondyloarthritis, dermatomyositis/polymyositis, systemic sclerosis, mixed connective tissue disease, etc.).
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    RJMty19 (CD19-CAR-DNT Cells)

    The trial is divided into two parts: Part A is a dose escalation trial with three dose groups (5×10\^6 CAR+ cells/kg, 1×10\^7 CAR+ cells/kg, 2×10\^7 CAR+ cells/kg at day 0), with 9-18 patients planned to be enrolled. Part B is a dose-expansion trial in which 3\~6 patients will receive RJMty19 infusions at RP2D dose levels

    Biological: RJMty19 (CD19-CAR-DNT cells)

Interventions

  • BiologicalRJMty19 (CD19-CAR-DNT cells)

    Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.

    Also known as: Fludarabine, Cyclophosphamide

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity (DLT)

    To evaluate the safety, tolerability, and determine the recommended dosage of RJMty19 for SLE subjects

    Time frame: Up to 28 days

  2. Maximum Tolerated Dose (MTD)

    MTD is the highest dose for DLT in ≤1/6 subjects

    Time frame: Up to 28 days

  3. Incidence of abnormalities

    Incidence of abnormalities in AE/SAE/AESI/laboratory tests/electrocardiograms/vital signs.

    Time frame: Up to 28 days

Secondary outcomes

  1. Pharmacokinetics (PK) indicator (Cmax)

    The peak concentration of CD19-CAR-DNT cells amplified in the peripheral blood (Cmax, detected by qPCR and Flow Cytometry).

    Time frame: Up to 28 days

  2. Pharmacokinetics (PK) indicator (AUC)

    CD19-CAR-DNT cells blood concentrations will be measured at different time points to evaluate the area under the curve (AUC). (AUC, detected by qPCR and Flow Cytometry)

    Time frame: Up to 90 days

  3. Pharmacokinetics (PK) indicator (CAR copy numbers)

    Changes in CAR copy numbers after injection of RJMty19

    Time frame: Up to 24 months

  4. Remission rate of SLE based on DORIS criteria

    cSLEDAI=0 and PGA \< 0.5

    Time frame: at 3 months, 6 months, 12 months and 24 months

  5. Remission rate of SLE based on LLDAS criteria

    SLEDAI-2K ≤ 4 points without manifestations of major organ and system involvement (renal, central nervous, cardiopulmonary, vasculitis, fever); No new disease activity compared to previous assessments (SLEDAI-2K); Physician's global assessment (PGA, 0-3) ≤1; prednisone dose (or equivalent) ≤ 7.5 mg/d; Use of stable doses of immunosuppressants and approved biologics.

    Time frame: at 3 months, 6 months, 12 months and 24 months

07

Study locations

4 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2024; primary completion for Dec 2026, 31 months later.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 31 months is above that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Apr 1, 2024
StartEst.
May 15, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Apr 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06340490
Lead sponsor
Guangdong Ruishun Biotech Co., Ltd
Responsible party
Sponsor
First posted
Apr 1, 2024
Start date
May 15, 2024 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 1, 2024

Study contacts

Haicun Xie
Contact
hcxie@wyzebiotech.com
+086-18358586096
Shuang Ye, MD, PhD
principal investigator · RenJi Hospital
Zhanguo Li, MD, PhD
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion